NXgenPort (NGP), has designed an innovative and transformative technology to maximize remote care in cancer patients requiring an implantable chemo-port catheter. Combining proven chemo-port efficacy with microchip and sensor technology, NGP measures, monitors and reports physiological body functions in vivo over the course of disease and treatment.
In this episode, Founder and CEO Kathy Skinner shares the details of how this port advances care for a very important patient population and how its quickly gaining momentum.
Elims is a social impact company that combines seriously effective oral care + real sustainability. They believe you don't have to compromise your health...
David Finkel is the Founder and CEO of Maui Mastermind®, one of the world’s premier business coaching companies with thousands of clients worldwide. He...
Ian Sarembock, MD - is a retired Coronary & Structural Interventionalist and was previously the Harold C. Schott Endowed Chair in Structural Heart at...
